Signalling the way to improve outcomes in obesity management
17:45-19:15, 13 May 2013, Hall 1C, Arena and Convention Centre Liverpool (AAC), Liverpool, UK
Chair: Nicholas Finer, London, UK
Lifestyle measures are the foundation of all strategies for weight reduction as well as the management of type 2 diabetes. In practice, however, only a minority of people achieve their targets for weight loss and/or glycaemic control with lifestyle measures alone. When this is the case, guidelines recommend that surgical and pharmacological options be considered. In this symposium we will review the gut-brain axis in weight control and how appropriate targeting of gut hormone action may facilitate improved outcomes. With the development of new therapies it is important to discuss how these agents achieve their effects and appreciate the full range of effects that can be expected when targeting different elements of the gut-brain axis. We will also consider how to make best use of these therapies alongside other treatment approaches, including lifestyle measures and bariatric surgery.
|17:45-17:50||Welcome and introduction||Nicholas Finer
|17:50-18:15||The gut-brain axis in weight control||Arne Astrup
|18:15-18:40||The impact of pharmacotherapies on appetite||Nicholas Finer
|18:40-19:05||Targeting gut hormones for improved outcomes||Lawrence Leiter